Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Plexpress Secures $2.3M to Commercialize TRAC High-Content Gene Expression Analysis Platform

Published: Thursday, April 19, 2012
Last Updated: Thursday, April 19, 2012
Bookmark and Share
Company targets applications including companion diagnostics and ADMET.

Plexpress has announced follow-on funding of up to $2.3M to commercialize its novel TRAC (Transcript Analysis with the aid of Affinity Capture) platform for high-content gene expression analysis.

The investment has been secured to commercialize the technology internationally, build up the ADMET screening service and develop TRAC specifically within the oncology sector.

Existing investors - Conor Technology Fund, VTT Ventures, Aloitusrahasto Vera and the Helsinki University Fund - as well as Tekes, the Finnish Funding Agency for Technology and Innovation, have invested $1.4M initially with further milestone payments of up to $900k.

As the potential applications and opportunities in genomic research continue to grow, the TRAC system is poised to provide the ideal method for the increased throughput and multiplex screening that the development of new therapies and diagnostics requires.

With TRAC, the expression of up to 30 genes can be routinely quantified in each plate well (30-plex), while thousands of samples can be processed quickly, easily and reproducibly.

The TRAC technology has been refined and validated over 10 years of development, initially at the Technical Research Centre of Finland, VTT, and subsequently at Plexpress, with over 50 separate projects completed successfully.

By avoiding the need for RNA extraction, cDNA conversion and amplification, the TRAC protocol takes only four hours to complete and RNA degradation is significantly reduced. This makes it fast, simple and cost-effective to implement, while lowering error rates and maximizing accuracy.

“This funding will enable Plexpress to pursue high value market opportunities, such as companion diagnostics and ADMET. TRAC provides significant benefits over existing technologies such as qPCR and microarrays, which do not offer either the throughput or the multiplexing that many genomics researchers require. Our early investors recognized these opportunities and have underlined their belief in TRAC with this continuing funding”, said Plexpress CEO, and leading expert in TRAC technology, Dr Jari Rautio.

Commenting on the renewed funding, MoB Managing Partner, Jari Mieskonen, of Conor Venture Partners said: “We are very happy that all current investors continued to support Plexpress in this follow-on investment round. The added involvement of Tekes gives us increased leverage for commercializing the TRAC technology and with the extremely positive feedback from key customers we foresee a fast market roll-out.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos